NZ227729A - Growth regulatory proteins, specifically amphiregulin, and its production - Google Patents

Growth regulatory proteins, specifically amphiregulin, and its production

Info

Publication number
NZ227729A
NZ227729A NZ227729A NZ22772989A NZ227729A NZ 227729 A NZ227729 A NZ 227729A NZ 227729 A NZ227729 A NZ 227729A NZ 22772989 A NZ22772989 A NZ 22772989A NZ 227729 A NZ227729 A NZ 227729A
Authority
NZ
New Zealand
Prior art keywords
amphiregulin
protein
cell
growth
cells
Prior art date
Application number
NZ227729A
Other languages
English (en)
Inventor
Mohammed Shoyab
Vickie L Mcdonald
James G Bradley
Gregory D Plowman
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/297,816 external-priority patent/US5115096A/en
Application filed by Oncogen filed Critical Oncogen
Publication of NZ227729A publication Critical patent/NZ227729A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ227729A 1988-01-25 1989-01-25 Growth regulatory proteins, specifically amphiregulin, and its production NZ227729A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14832788A 1988-01-25 1988-01-25
US18188488A 1988-04-15 1988-04-15
US07/297,816 US5115096A (en) 1988-04-15 1989-01-17 Amphiregulin: a bifunctional growth modulating glycoprotein

Publications (1)

Publication Number Publication Date
NZ227729A true NZ227729A (en) 1992-02-25

Family

ID=27386678

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ227729A NZ227729A (en) 1988-01-25 1989-01-25 Growth regulatory proteins, specifically amphiregulin, and its production

Country Status (24)

Country Link
US (1) US5830995A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH02104596A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1038126A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT399720B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU623109B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1004201A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH681080A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3902157A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK29989A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2016432A6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI890312L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2628109B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2214185B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR1000849B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT52545A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE61146B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL89033A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1229504B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY104980A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8900178A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO177788C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ227729A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE504554C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU16989A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262298A (en) * 1989-05-12 1993-11-16 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Method to assess the ability of a substance to inhibit or stimulate keratinocyte autocrine factor production
CA2037440A1 (en) * 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
EP0559769B1 (en) * 1990-10-16 2001-02-07 The Children's Medical Center Corporation Heparin binding mitogen with homology to epidermal growth factor (egf)
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6235884B1 (en) 1993-06-15 2001-05-22 Scios Nova, Inc. Heparin binding mitogen with homology to epidermal growth factor (EGF)
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
EP0871663A2 (en) * 1995-12-22 1998-10-21 Innogenetics N.V. New form of amphiregulin, methods for producing and using the same and compositions comprising the same
US6852506B1 (en) 1996-04-10 2005-02-08 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein
US5948889A (en) * 1996-05-21 1999-09-07 Case Western Reserve University Compositions and methods for screening antimicrobials
AU752206B2 (en) * 1997-04-11 2002-09-12 Human Genome Sciences, Inc. Extracellular/epidermal growth factor like protein
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
ATE433107T1 (de) * 2000-10-10 2009-06-15 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
WO2002059376A1 (en) * 2001-01-23 2002-08-01 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer
AU2002252253A1 (en) * 2001-03-09 2002-09-24 Rico Buchli Epitope testing using hla
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
RU2224255C2 (ru) * 2002-04-15 2004-02-20 Государственное учреждение Нижегородский научно-исследовательский кожно-венерологический институт Способ прогнозирования течения псориаза
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US7482427B2 (en) * 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
CA2496732A1 (en) * 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20080292629A1 (en) * 2004-05-27 2008-11-27 Yhengbin Yao System Clock Generation Circuit
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
DE102011056933A1 (de) * 2011-12-22 2013-06-27 Bayerische Motoren Werke Aktiengesellschaft Interieurbauteil für ein Kraftfahrzeug
WO2015106224A2 (en) 2014-01-12 2015-07-16 Hugh Mctavish Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3373954A4 (en) * 2015-11-10 2019-07-03 Proteothera, Inc. PROCESS FOR PREPARING AND CLEANING MATRIX-BINDING FUSION PROTEINS BY ION EXCHANGE CHROMATOGRAPHY
CA3059593A1 (en) 2017-05-21 2018-11-29 Igf Oncology, Llc An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
CN110531023B (zh) * 2019-10-08 2024-06-14 安徽理工大学 一种薄层色谱分析仪
CN112779209B (zh) * 2019-11-08 2023-01-24 合肥中科普瑞昇生物医药科技有限公司 原代乳腺上皮细胞培养基、培养方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein

Also Published As

Publication number Publication date
YU16989A (en) 1991-10-31
DE3902157A1 (de) 1989-07-27
CN1038126A (zh) 1989-12-20
CH681080A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-01-15
GB2214185B (en) 1992-06-17
IT8919186A0 (it) 1989-01-25
AU2876989A (en) 1989-08-24
JPH02104596A (ja) 1990-04-17
IL89033A0 (en) 1989-08-15
NO177788C (no) 1995-11-22
GR1000849B (el) 1993-02-17
FI890312A7 (fi) 1989-07-26
FR2628109B1 (fr) 1993-04-09
IE890207L (en) 1989-07-25
FR2628109A1 (fr) 1989-09-08
GB8901469D0 (en) 1989-03-15
FI890312A0 (fi) 1989-01-20
AT399720B (de) 1995-07-25
IT1229504B (it) 1991-09-03
SE504554C2 (sv) 1997-03-03
FI890312L (fi) 1989-07-26
MY104980A (en) 1994-07-30
DK29989D0 (da) 1989-01-24
ES2016432A6 (es) 1990-11-01
BE1004201A5 (fr) 1992-10-13
NO890299L (no) 1989-07-26
SE8900247L (sv) 1989-07-26
IL89033A (en) 1994-05-30
ATA14789A (de) 1994-11-15
GB2214185A (en) 1989-08-31
US5830995A (en) 1998-11-03
NO177788B (no) 1995-08-14
SE8900247D0 (sv) 1989-01-24
NL8900178A (nl) 1989-08-16
AU623109B2 (en) 1992-05-07
DK29989A (da) 1989-07-26
GR890100037A (en) 1990-01-31
HUT52545A (en) 1990-07-28
IE61146B1 (en) 1994-10-05
NO890299D0 (no) 1989-01-24

Similar Documents

Publication Publication Date Title
AU623109B2 (en) Amphiregulin: a novel bifunctional growth modulating glycoprotein
US5115096A (en) Amphiregulin: a bifunctional growth modulating glycoprotein
JP2957974B2 (ja) エリスロポエチン活性を有するタンパク質の製造方法
US5221620A (en) Cloning and expression of transforming growth factor β2
EP0527806B1 (en) Epithelins: novel cysteine - rich growth modulating proteins
DK175412B1 (da) Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne
CN1191491A (zh) 结缔组织生长因子
NO175312B (no) Fremgangsmåte for rensing av et polypeptid med en del av den strukturelle oppbygning til blodplate-avledet vekstfaktor, samt monoklonalt antistoff som er spesifikt for en epitop derav
FI109206B (fi) Interleukiini-1 inhibiittoreita koodittavat DNA-sekvenssit, niitä sisältävät vektorit ja isäntäsolut sekä menetelmä interleukiini-1-inhibiittoreiden valmistamiseksi
Abraham et al. Human basic fibroblast growth factor: nucleotide sequence, genomic organization, and expression in mammalian cells
US5618715A (en) Oncostatin M and novel compositions having anti-neoplastic activity
AU626791B2 (en) Oncostatin m and novel compositions having anti-neoplastic activity
US5175255A (en) Methods for purification of platelet-derived growth factor
US5451506A (en) Oncostatin M and novel compositions having anti-neoplastic activity
FI104424B (fi) Menetelmä onkostatiini M -mutantin valmistamiseksi
NO179453B (no) Fremgangsmåte for fremstilling av terapeutisk aktivt amphiregulin, vertscelle som produserer proteinet, rekombinant vektor inneholdt i vertscellen, samt nukleotidsekvens som koder for proteiner med amphiregulinaktivitet
JP2779621B2 (ja) モノクローナル抗体，ハイブリドーマ，それらの製造法およびそれらの用途
JPH05292995A (ja) モノクローナル抗体，その製造法および用途
DD296700A5 (de) Verfahren zur herstellung einer fuer das amphiregulin-gen kodierenden nucleotidsequenz und von modifizierten zellen, welche diese nucleotidsequenz enthalten.
LU87442A1 (fr) L'amphireguline:une nouvelle glycoproteine bifonctionnelle modulatrice de la croissance
MXPA98009347A (en) Mp52 anti-hum monoclonal antibody